Aquestive Therapeutics, Inc. (NASDAQ:AQST) is expected to report third quarter earnings results, after market close, on Wednesday 4th November 2020.
Analysts polled by Thomson Reuters anticipate third quarter loss of $ 0.46 per share.
Looking ahead, the full year loss are expected at $ 1.5 per share on the revenues of $ 47.32 million.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 35.00 million ~ $ 45.00 million
Click Here For More Historical Outlooks Of Aquestive Therapeutics, Inc.
Previous Quarter Performance
Aquestive Therapeutics, Inc. outlined loss for the second quarter of $ 0.07 per share, from the revenue of $ 21.68 million. The quarterly revenues increased 94.79 percent compared with the same quarter last year. The consensus estimates are loss of $ 0.43 per share from $ 8.77 million in revenue. The bottom line results beat street analysts by $ 0.36 or 83.72 percent, at the same time, top line results outshined analysts by $ 12.91 million or 147.21 percent.
Stock Performance
Shares of Aquestive Therapeutics, Inc. traded up $ 0.50 or 10.42 percent on Tuesday, reaching $ 5.30 with volume of 944.50 thousand shares. Aquestive Therapeutics, Inc. has traded high as $ 5.40 and has cracked $ 4.91 on the downward trend
According to the previous trading day, closing price of $ 5.30, representing a 240.43 % increase from the 52 week low of $ 1.41 and a 52 % decrease over the 52 week high of $ 10.00.
The company has a market capital of $ 178.18 million and is part of the Healthcare sector and Biotechnology industry.
Recent Analyst recommendations
- On 28th September 2020, maintained by HC Wainwright at Buy rating, with $ 14.00 target price.
- On 28th September 2020, maintained by RBC Capital at Outperform rating, with $ 7.00 target price.
Aquestive Therapeutics, Inc., a specialty pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery in the United States and internationally. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of recurrent epileptic seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of Amyotrophic Lateral Sclerosis.
